Discovery/R&D
-
Leveraging Lymph Nodes With Elicio's Dr. Peter DeMuth
10/30/2022
MIT-born startup Elicio Therapeutics' novel Amphiphile Technology Platform is designed to directly engage the lymphatic system in the deployment and delivery of therapeutic payloads. We caught up with Chief Scientific Officer Peter DeMuth, Ph.D. at Elicio HQ in Boston to learn how the platform works, and how it's driving rapid clinical progress for the company's robust pipeline of therapeutic vaccines in oncology, as a cell therapy amplifier in liquid and solid tumor indications, and in prophylactic vaccines for infectious diseases like COVID-19. Dr. DeMuth also shares his journey as a young scientific founder, how he's managed the transition from academic scientist to the C-suite, and how he leans into his scientific training to make a killer home brew.
-
BoB@JPM: Gene Writing With Tessera's Michael Severino, M.D.
2/26/2023
Flagship Pioneering plucked Michael Severino, M.D. away from AbbVie to run point at Tessera, a startup it's backed to pioneer a new category of genetic medicine it calls gene writing. The Business of Biotech caught up with Severino at the JP Morgan Healthcare Conference in San Francisco last month. We learned what lured him away from leadership positions at Merck, Amgen, and AbbVie, how gene writing differs from gene therapy and gene editing, why the team at Tessera believes its technologies can write and rewrite DNA at the scales necessary to cure most genetic diseases, and where he plans to take the company from here.
-
COO Liftoff With Rocket Pharmaceuticals' Kinnari Patel, PharmD
7/12/2023
Chief Operating Officer is arguably the toughest job in the emerging biopharma C-suite. HR, CMC, regulatory affairs, legal, PR, you name it, the COO touches it, and practically everything rolls up to her. This week's episode of the Business of Biotech brings us to a president and COO who's also a mom, a volunteer, and an advocate for diversity and equality in biopharma. That advocacy isn't just lip service, by the way. Here, Rocket Pharmaceuticals' Kinnari Patel, PharmD, shares on the real, practical, replicable steps Rocket takes to build a diverse and equitable work environment, how the fruits of that effort have proven important to the company's success, and where Rocket is taking its high-flying gene therapy act next.
Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!
-
Reprogramming Human Cells With bit.bio's Mark Kotter, M.D.
2/12/2024
The concept of programmable biology is fueling a new breed of biotech, one that requires the marriage of computational and traditional science (and both computational and traditional scientists) on the entire journey from discovery to commercial. Bit.bio is exemplary of this new breed.
-
Democratizing Biologics With Lumen Bioscience's Brian Finrow, J.D. & Craig Behnke, Ph.D.
12/1/2021
Making powerful and curative biologic therapies accessible to patients from all walks of life, and all corners of the globe, requires radically innovative thinking. On this episode of the Business of Biotech, Lumen Bioscience's Co-Founder and CEO Brian Finrow, J.D. and EVP of Production/Development Craig Behnke, Ph.D. discuss a novel approach: developing therapeutic proteins from readily-available food algae spirulina. It's driving a diverse pipeline of candidates into the clinic, for indications reaching from the gut to the heart and lungs.
-
Academia + Industry with BridgeBio's Dr. Michael Henderson
6/21/2021
BridgeBio has a whopping 30+ pre-clinical to clinical-stage candidates in its pipeline representing an impressive array of modalities and targets. It boasts a couple of commercial wins under its belt. The company is no stranger to developing business strategies for success. Central to that success are partnerships with scientists and researchers to fuel pipeline expansion. On this episode of The Business of Biotech, BridgeBio Chief Business Officer Michael Henderson, M.D. walks us through the formula behind the company's academia-led growth strategy.
-
Live Biologics & The Microbiome With 4D pharma's Duncan Peyton
5/9/2022
4D pharma's flagship early-stage clinical candidates are live biotherapeutics, a relatively new class of biologics that seek to impact disease state by modulating the microbiome. CEO Duncan Peyton is leading the effort to understand how the health of the microbiome relates to a wide range of diseases, including immuno-oncology, central nervous system disorders, respiratory disease, auto immune indications, and gastro intestinal disease. 4D pharma is even working on a live biotherapeutic vaccine platform. Join Duncan on this episode of the Business of Biotech as we discuss this new frontier of therapeutic exploration.
-
Computational Drug Discovery With Gain Therapeutics' Matthias Alder
1/11/2023
Gain Therapeutics' newly-appointed CEO Matthias Alder offers up a deep, yet abundantly clear explanation of how his company is applying compute power to speed up drug discovery. At Gain, computational models help researchers winnow down not just which molecules might have therapeutic effect, but also how adept those molecules will be at binding—and staying bound—to their target. It's not just theory, either. On this episode of the Business of Biotech, Alder shares on how the virtual successes seen on Gain's servers have translated in the wet lab, and how they've contributed to the company's fast-growing preclinical pipeline.
-
Genomically-Guided Medicine with Elevation Oncology's Shawn Leland, PharmD, RPh
12/13/2021
Elevation Oncology is taking a new approach to leveraging the genome to guide development of its precision therapeutic development efforts. Its first step is improving both the accuracy of and accessibility to genomic testing for cancer patients. In tandem, the company is in the clinic with its lead candidate seribantumab for cancer patients with a solid tumor of any origin that expresses a genomic change called an NRG1 fusion. On this episode of the Business of Biotech, Founder & CEO Shawn Leland, PharmD, RPh takes us inside the company's unique approach.
-
Turning The Liver Into A mAb Factory With Homology's Arthur Tzianabos, Ph.D.
11/15/2021
Homology Medicines' approaches to gene therapy and gene editing have the potential to seriously disrupt both the cell/gene therapy space \_and\_ the mAb manufacturing and administration paradigms as we know them. On this episode of the Business of Biotech, Homology President & CEO Arthur Tzianabos, Ph.D. shares the company's approach and supports its rationale for investing in its own development and manufacturing capacity.